States step up Zyprexa marketing probe

Share this article:
Eli Lilly has been asked by state prosecutors in Illinois and Vermont to turn over information about the way it promoted its Zyprexa antipsychotic drug, reports The New York Times. The Illinois attorney general’s office demanded that Lilly release marketing materials, e-mail messages, and other documents with information about promotion of Zyprexa. Vermont investigators issued a similar order. The states are part of a coordinated five-state civil investigation into the way Lilly promoted Zyprexa, notes the Times. The states are investigating whether Lilly tried to hide Zyprexa’s risk of causing weight gain and other risks associated with diabetes and whether the company promoted Zyprexa for off-label uses. In a statement, Lilly said it would cooperate with the investigations and had done nothing wrong. Federal prosecutors in Philadelphia also have recently escalated their own investigation into Lilly’s marketing of Zyprexa. Among other state-level investigations, attorneys general in California and Florida may seek to recover Medicaid payments that the states made for Zyprexa. The commercial success of the drug could mean any fine or cost recovery could be sizable. Zyprexa had sales of $4.2 billion last year and about $30 billion since its introduction in 1996. A review of documents in the Times last month claimed Lilly played down the risks of Zyprexa to doctors and that it encouraged off-label use. Lilly has denied any wrongdoing and said it provided all relevant information to doctors and regulators. The company has also said it did not promote Zyprexa for conditions other than schizophrenia or bipolar disorder.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...